今开:6.26 | 昨收:6.33 |
最高:6.675 | 最低:6.219 |
涨停价:0.0 | 跌停价:0.0 |
总市值:1.8493119E7 |
KALA BIO(KALA)03-04 20:35
$KALA BIO(KALA)$ 8-K Current report, items 7.01 and 8.01 Accession Number: 0001558370-24-002313 Act: 34 Size: 149 KB 网页链接查看全文
KALA BIO(KALA)03-29 20:05
$KALA BIO(KALA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001558370-24-004325 Act: 34 Size: 316 KB 网页链接查看全文
KALA BIO(KALA)02-15 02:15
$KALA BIO(KALA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001977548-24-000004 Act: 34 Size: 79 KB 网页链接查看全文
KALA BIO(KALA)03-29 20:15
$KALA BIO(KALA)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-24-004326 Act: 34 Size: 14 MB 网页链接查看全文
KALA BIO(KALA)03-29 20:25
$KALA BIO(KALA)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001558370-24-004330 Act: 33 Size: 128 KB 网页链接查看全文
KALA BIO(KALA)02-17 05:15
$KALA BIO(KALA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001273087-24-000050 Act: 34 Size: 81 KB 网页链接查看全文
KALA BIO(KALA)01-30 05:45
$KALA BIO(KALA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001319244-24-000016 Act: 34 Size: 95 KB 网页链接查看全文
KALA BIO(KALA)03-26 20:35
$KALA BIO(KALA)$ 8-K Current report, items 1.01, 3.02, 5.03, and 9.01 Accession Number: 0001558370-24-003889 Act: 34 Size: 940 KB 网页链接查看全文
KALA BIO(KALA)03-30 04:15
$KALA BIO(KALA)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001104659-24-041146 Act: 33 Size: 13 KB 网页链接查看全文
KALA BIO(KALA)04-20 04:15
$KALA BIO(KALA)$ PRE 14A Other preliminary proxy statements Accession Number: 0001558370-24-005362 Act: 34 Size: 1 MB 网页链接查看全文
美股医药Z博士2018-10-08 22:24
$Kala Pharmaceuticals, Inc.(KALA)$ 公司主打眼科领域,干眼症药物3期结果虽然喜忧参半,但FDA同意开展另一个三期。同时另一款手术后消炎用激素类药物8月份获批。公司刚刚完成一轮增发,账面现金充足,市值仅2亿左右。上周五传出大股东增持2000万,利好。股价基本已经是ALL TIME LOW。建议买入长...查看全文
淘沙见金2017-12-18 09:19
$Kala Pharmaceuticals, Inc.(KALA)$ 年底之前最后一个大的binary event - KPI-121针对干眼症的临床三期结果。之前的二期试验没有满足统计学的显著意义,这次三期要达到主要试验终点难度不小。KPI-121 针对的主要是急性干眼症,跟针对慢性干眼症Allergan$艾尔建医疗(AGN)$ 的 Restasis和 Shire $Sh...查看全文
一周一次的见面会又来了,还是我→美股风向标。致力于追踪热门美股优质标的,挖掘更多投资机会。接下来我们来看看本周有哪些重要的标的可以关注吧! 1、Kala制药公司 $KALA 表示,FDA接受了其主要候选产品KPI-012——治疗眼睛罕见疾病的研究... 网页链接
智通财经APP获悉,专注于眼部护理的全球医疗专业公司爱尔康(ALC.US)宣布,同意从生物制药公司Kala Pharma(KALA.US)手中收购EYSUVIS(0.25%氯替泼诺混悬滴眼液)和INVELTYS(1%氯替泼诺混悬滴眼液)。 据了解,EYSUVIS是首个也是唯一一个获FD... 网页链接
$KALA BIO(KALA)$ PRE 14A Other preliminary proxy statements Accession Number: 0001558370-24-005362 Act: 34 Size: 1 MB 网页链接
$KALA BIO(KALA)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001104659-24-041146 Act: 33 Size: 13 KB 网页链接
$KALA BIO(KALA)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001558370-24-004330 Act: 33 Size: 128 KB 网页链接
$KALA BIO(KALA)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-24-004326 Act: 34 Size: 14 MB 网页链接
$KALA BIO(KALA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001558370-24-004325 Act: 34 Size: 316 KB 网页链接
$KALA BIO(KALA)$ 8-K Current report, items 1.01, 3.02, 5.03, and 9.01 Accession Number: 0001558370-24-003889 Act: 34 Size: 940 KB 网页链接
$KALA BIO(KALA)$ 8-K Current report, items 7.01 and 8.01 Accession Number: 0001558370-24-002313 Act: 34 Size: 149 KB 网页链接
$KALA BIO(KALA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001273087-24-000050 Act: 34 Size: 81 KB 网页链接
$KALA BIO(KALA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-023734 Act: 34 Size: 96 KB 网页链接
$KALA BIO(KALA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001977548-24-000004 Act: 34 Size: 79 KB 网页链接